Company Filing History:
Years Active: 2017-2022
Title: Michael Schmidt: Innovator in Clostridial Neurotoxins
Introduction
Michael Schmidt is a prominent inventor based in Potsdam, Germany. He has made significant contributions to the field of biotechnology, particularly in the development of recombinant clostridial neurotoxins. With a total of 4 patents, his work has the potential to impact various medical applications.
Latest Patents
One of his latest patents focuses on recombinant clostridial neurotoxins with increased duration of effect. This invention relates to novel recombinant clostridial neurotoxins that exhibit an extended duration of effect. The methods for manufacturing these neurotoxins involve inserting a nucleic acid sequence coding for a random coil domain into a nucleic acid sequence coding for a parental clostridial neurotoxin. The expression of the recombinant nucleic acid sequence occurs in a host cell. Additionally, the invention includes novel recombinant single-chain precursor clostridial neurotoxins, nucleic acid sequences encoding these neurotoxins, and pharmaceutical compositions that incorporate the recombinant clostridial neurotoxin with increased duration of effect.
Career Highlights
Michael Schmidt is currently associated with Merz Pharma GmbH & Co. KGaA, where he continues to innovate in the field of biotechnology. His work has garnered attention for its potential applications in medicine and therapeutics.
Collaborations
Some of his notable coworkers include Fred Hofmann and Jürgen Frevert, who contribute to the collaborative efforts in advancing their research and development projects.
Conclusion
Michael Schmidt's innovative work in recombinant clostridial neurotoxins showcases his commitment to advancing biotechnology. His contributions are paving the way for new therapeutic options in medicine.